Introduction Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …

Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …

Background About 20% of advanced non–small-cell lung cancer (NSCLC) cases harbor
somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor …

9007 Background: In JO25567 (Clinical trials registry number. JapicCTI-111390), EB
significantly prolonged progression-free survival (PFS) in patients with NSCLC with …

9506 Background: In NEJ026, a phase III trial comparing bevacizumab plus erlotinib (BE) to
erlotinib monotherapy (E) for EGFR-mutated non-small-cell lung cancer (NSCLC), we …

Background This study is an open-labeled, randomized, multicenter phase III study to
investigate the efficacy and safety of bevacizumab (B) with or without erlotinib (E) in Chinese …

Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …

Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …

9006 Background: Development of treatment for EGFR-mutated non-small-cell lung cancer
(NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. Combinations …

8005 Background: Despite the development of EGFR tyrosine kinase inhibitors, median
progression-free survival (PFS) is only about 13 months in patients with EGFR mutation …